- Home
- DVAX
as 07-05-2024 12:32pm EST
Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of HEPLISAV-B (Hepatitis B Vaccine (Recombinant), Adjuvanted), operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product and HEPLISAV-B.
| Founded: | 1996 | Country: | United States |
| Employees: | N/A | City: | EMERYVILLE |
| Market Cap: | 1.5B | IPO Year: | 2004 |
| Target Price: | $25.33 | AVG Volume (30 days): | 2.2M |
| Analyst Decision: | Buy | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 0.06 | EPS Growth: | -96.18 |
| 52 Week Low/High: | $10.48 - $15.15 | Next Earning Date: | 08-01-2024 |
| Revenue: | $236,149,000 | Revenue Growth: | -63.98% |
| Revenue Growth (this year): | 25.08% | Revenue Growth (next year): | 22.51% |
Stock Insider Trading Activity of Dynavax Technologies Corporation (DVAX)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Burgess Justin | DVAX | Chief Accounting Officer | Mar 1 '24 | Sell | $12.78 | 7,101 | $90,750.78 | 13,425 | SEC Form 4 |
| Burgess Justin | DVAX | Chief Accounting Officer | Mar 1 '24 | Sell | $12.78 | 13,425 | $171,571.50 | 0 | SEC Form 4 |
| Janssen Robert | DVAX | SVP and CMO | Jan 4 '24 | Sell | $15.00 | 1,500 | $22,500.00 | 49,925 | SEC Form 4 |
| Novack David F | DVAX | President & COO | Jan 2 '24 | Sell | $14.45 | 9,000 | $130,050.00 | 3,187 | SEC Form 4 |
| Novack David F | DVAX | President & COO | Dec 1 '23 | Sell | $13.56 | 20,000 | $271,200.00 | 3,187 | SEC Form 4 |
| Novack David F | DVAX | President & COO | Nov 3 '23 | Sell | $15.00 | 20,000 | $300,000.00 | 3,187 | SEC Form 4 |
Latest Dynavax Technologies Corporation News
DVAX Breaking Stock News: Dive into DVAX Ticker-Specific Updates for Smart Investing
Argus Research
3 days ago
DVAX: What does Argus have to say about DVAX?
Clinical Trials Arena
7 days ago
Dynavax doses first subject in Phase I/II shingles vaccine trial
MT Newswires
8 days ago
Dynavax Reports First Participant Dosed in Shingles Vaccine Trial
PR Newswire
8 days ago
Dynavax Initiates Phase 1/2 Study of Novel Shingles Vaccine Program
GlobeNewswire
25 days ago
$6.6 Billion Digital X-ray Market, 2024-2029: Development of AI-based Digital X-Ray Systems Present Business Opportunities
Motley Fool
25 days ago
2 Reasons to Buy Rivian Stock (and 1 Big Reason to Sell)
CNW Group
25 days ago
DFR Gold Inc. Announces Amendment of WUO Land Option and Insider Loans
Investor's Business Daily
25 days ago
Walmart Stock Climbs After Dow Jones Giant Receives Upgrade, Major Price Target Hike
Share on Social Networks:
Disclaimer
The information presented on this page, "DVAX Dynavax Technologies Corporation - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.